Otonomy, Inc. is a biopharmaceutical company, focuses on the development of therapeutics for neurotology in the United States. The company's lead product candidate is OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine that is being developed to treat tinnitus. In addition, the company has two Phase II clinical trials for OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor for the treatment of speech in noise hearing difficulties and repair cochlear synaptopathy remodeling caused by acute hearing loss.

Latest articles

Larry Page: The Mastermind Behind Google

Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.

24 Apr 2024

Mark Leonard: The Mysterious Brain Behind Constellation Software

Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.

24 Apr 2024

Sundar Pichai: CEO of Alphabet and Google

Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.

19 Apr 2024

Ticker symbol

Country

🇺🇸 United States